9SO.F · Solasia Pharma K.K

-

Please sign in to comment on 9SO.F

1 Comment

Admin

4 years ago

Solasia Pharma K.K is currently in a long term uptrend where the price is trading 2.8% above its 200 day moving average.

From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.6.

Solasia Pharma K.K's total revenue sank by 83.6% to $167M since the same quarter in the previous year.

Its net income has dropped by 1023.1% to $-2B since the same quarter in the previous year.

Finally, its free cash flow fell by 212.4% to $-554M since the same quarter in the previous year.

Based on the above factors, Solasia Pharma K.K gets an overall score of 2/5.

Exchange	F
CurrencyCode	EUR
ISIN	JP3436500007
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

Market Cap	46M
PE Ratio	None
Target Price	None
Beta	1.31
Dividend Yield	None

ABOUT

Solasia Pharma K.K

Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers Episil, an oral liquid for oral mucositis/stomatitis; DARVIAS, an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso for chemotherapy induced nausea and vomiting. It also develops SP-04, which is in preclinical trial development to treat chemotherapy peripheral neuropathy; and SP-04, which is in preclinical trial development for the treatment of colorectal cancer. The company was founded in 2006 and is based in Tokyo, Japan.

9SO.F · Solasia Pharma K.K

-

Solasia Pharma K.K

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Solasia Pharma K.K using a moving average strategy